News and Announcements
Leaf Resources Investor Presentation June 2016
- Published June 21, 2016 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
20th June 2016, ASX Announcement
Attached is the company’s new presentation detailing our proprietary Glycell™ process, the market opportunities for the process and projects we are currently developing.
Company Overview
Leaf Resources is a green chemical company that uses plant waste/biomass to create industrial chemicals to replace petrochemicals in manufacturing.
- Patent pending Glycell™ process that converts plant biomass into industrial sugars (a key component used to create green/sustainable chemicals)
- Large cost advantage over other processes that create industrial sugars
- Glycell™ is well-suited for a low-carbon world as it is sustainable, carbon friendly and cuts carbon emissions
To view the full presentation, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
